HomeGenetics UnderstandingTestingWhat is circulating tumor DNA and how is it used to diagnose and manage cancer?
Back to Testing
What is circulating tumor DNA and how is it used to diagnose and manage cancer?
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Testing

What is circulating tumor DNA and how is it used to diagnose and manage cancer?

Circulating tumor DNA (ctDNA) consists of small fragments of genetic material released into the bloodstream by dying cancer cells, offering a non-invasive way to monitor tumor activity.

Overview

Circulating tumor DNA (ctDNA) refers to DNA found in the bloodstream that originates from cancerous cells and tumors. Most DNA is typically contained within a cell’s nucleus. However, as a tumor grows, cells die and are replaced by new ones. During this process, the dead cells break down and release their contents—including DNA—into the bloodstream. These ctDNA fragments are small, usually comprising fewer than 200 nucleotides (building blocks) in length.

The quantity of ctDNA present in an individual varies based on the type of tumor, its location, and the stage of the cancer.

Clinical Applications

The detection and analysis of ctDNA can be beneficial in several clinical scenarios:

  • Detecting and diagnosing a tumor: Because tumor DNA contains multiple genetic changes (variants) that differ from an individual's normal DNA, finding these differences aids in tumor detection. This can reduce the need for a tumor biopsy, which may be challenging if the tumor is in a difficult-to-access location, such as the lung or brain.
  • Guiding tumor-specific treatment: Analyzing the genome of tumor cells via ctDNA can help doctors identify the most effective treatment. Currently, U.S. Food and Drug Administration approval for using ctDNA testing to personalize cancer treatment is limited.
  • Monitoring treatment: A decrease in the quantity of ctDNA in the blood suggests that the tumor is shrinking and the treatment is successful.
  • Monitoring remission: A lack of ctDNA in the bloodstream during periods with no symptoms indicates that the cancer has not returned.

Frequently Asked Questions

ctDNA is highly useful for cancers that shed DNA into the bloodstream, such as lung, colorectal, and breast cancers. However, for tumors that release little ctDNA (e.g., some brain tumors), a tissue biopsy may still be necessary. Discuss with your oncologist whether ctDNA is appropriate for your case.
The blood draw is similar to a routine lab test and carries minimal risk—possible bruising or discomfort at the puncture site. No additional radiation or invasive procedures are involved.
Undetectable ctDNA after surgery suggests that no residual tumor DNA is circulating, which is a good prognostic sign. However, it does not guarantee cure; regular follow‑up imaging and clinical exams are still required.
The frequency depends on the cancer type and treatment plan. Many oncologists schedule ctDNA testing every 4–6 weeks during active therapy and every 3–6 months during remission monitoring. Your oncology team will tailor the schedule to your specific situation.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab

Sök
Om ossVillkor och policyVanliga frågorKontakta oss